Alaska Chapter of the American College of Cardiology

Conduction Abnormalities Requiring PPM Common After TAVR, State-of-the-Art Review Finds
As TAVR is increasingly used as an alternative to surgical aortic valve replacement (SAVR), conduction abnormalities, such as new onset left bundle branch block (LBBB) and high-grade atrioventricular block (AVB), requiring permanent pacemaker (PPM) implantation remain common following TAVR, according to a state-of-the-art review published Jan. 18 in JACC: Cardiovascular Interventions.
Empagliflozin in Non-diabetic Heart Failure Patients With Reduced Ejection Fraction
The goal of the EMPATROPISM trial was to evaluate empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, compared with placebo among non-diabetic patients with heart failure with reduced ejection fraction (HFrEF).
Unplanned PCI After TAVR
What is the incidence, timing, and cause of unplanned percutaneous coronary intervention (PCI) after transcatheter aortic valve replacement (TAVR)?
Long-Term Beta-Blocker Use After MI in Patients Without HF
Are beta-blockers cardioprotective among patients with stable, optimally treated myocardial infarction (MI) and no heart failure (HF)?
Cerebral Protection Devices for TAVR Patients
What is the impact of cerebral protection devices on outcomes during transfemoral transcatheter aortic valve replacement (TAVR) in real-world clinical practice?